Bifunctional Peptide with Mucoadhesive and Virus Binding Properties

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a bifunctional peptide that can bind both mucus (through a mucin-binding component, such as trefoil factor 3) and various respiratory viruses (such as SARS-CoV-2, influenza, and others) via a virus-binding component. The peptide attaches to mucosal surfaces (e.g., in the nose or respiratory tract) and captures viruses before they can infect cells, thereby enhancing the natural protective barrier of mucus against viral infections.

Use CasesContent extracted from patent full text and abstract with AI.

• Nasal or inhalation sprays for the prevention of respiratory viral infections including SARS-CoV-2, influenza, and rhinoviruses.
• Therapeutic adjunct to reduce viral load and spread in already infected individuals.
• Prophylactic treatment during epidemics or pandemics to supplement vaccines and hygiene measures.
• Augmenting mucosal immunity in immunocompromised or high-risk patients.
• Potential use in veterinary medicine to protect animals from respiratory viruses.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a modular, adaptable system to target multiple respiratory viruses by switching the virus-binding component.
• Strengthens the body’s natural mucosal defenses without relying solely on immune response or traditional antivirals.
• Reduces the probability and severity of infection by trapping viruses at the point of entry.
• Low expected side effects as components are derived from human proteins.
• Can be delivered in easy-to-use forms like sprays, suitable for broad public or clinical use.
• Potential to limit viral transmission and shedding, benefiting community health.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a bifunctional peptide comprising a virus binding moiety (2) and a mucin binding moiety (1) covalently bound to the virus binding moiety (2). The virus binding moiety is chosen from peptides binding to SARS-CoV-2, to influenza A, to influenza B, to rhinoviruses and other enteroviruses, to human parainfluenza virus, and/or to metapneuvirus. The mucin binding moiety is chosen from lectins such as trefoil factor 3.